alleen voor onderzoeksdoeleinden
Cat.nr.S1103
| Gerelateerde doelwitten | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Casein Kinase |
|---|---|
| Overig Aurora Kinase Inhibitoren | Hesperadin Barasertib-HQPA (AZD2811) Alisertib (MLN8237) Tozasertib (VX-680) MLN8054 Danusertib (PHA-739358) MK-5108 TCS7010 (Aurora A Inhibitor I) AMG-900 PHA-680632 |
| Cellijnen | Assaytype | Concentratie | Incubatietijd | Formulering | Activiteitsbeschrijving | PMID |
|---|---|---|---|---|---|---|
| human EoL-1-cell | Growth inhibition assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50=0.18678 μM | ||||
| MCF7 cell | Proliferation assay | Antiproliferative activity against MCF7 cell line, IC50=0.198 μM | ||||
| human P12-ICHIKAWA cell | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=0.22441 μM | ||||
| human KARPAS-45 cell | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=0.38128 μM | ||||
| human ES3 cell | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=0.4732 μM | ||||
| human ES8 cell | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50=0.49806 μM | ||||
| human TE-11 cell | Growth inhibition assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50=0.53703 μM | ||||
| human RS4-11 cell | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=0.5544 μM | ||||
| human MOLT-16 cell | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=0.60961 μM | ||||
| human RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=0.70656 μM | ||||
| human MV-4-11 cell | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.7963 μM | ||||
| human SW954 cell | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50=0.83635 μM | ||||
| human BE-13 cell | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=0.84418 μM | ||||
| human MOLT-4 cell | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=0.89978 μM | ||||
| human NBsusSR cell | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=0.91387 μM | ||||
| human H9 cell | Growth inhibition assay | Inhibition of human H9 cell growth in a cell viability assay, IC50=0.92979 μM | ||||
| human A172 cell | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50=0.98411 μM | ||||
| human ES5 cell | Growth inhibition assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50=1.00248 μM | ||||
| human SBC-1 cell | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=1.03928 μM | ||||
| human NCI-H209 cell | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=1.16602 μM | ||||
| human NKM-1 cell | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=1.16798 μM | ||||
| human NCI-H720 cell | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=1.20627 μM | ||||
| human KE-37 cell | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=1.21388 μM | ||||
| human SW48 cell | Growth inhibition assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50=1.23155 μM | ||||
| human IST-SL1 cell | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=1.31727 μM | ||||
| human SK-NEP-1 cell | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=1.36498 μM | ||||
| human NOMO-1 cell | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50=1.36725 μM | ||||
| human DOHH-2 cell | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=1.40276 μM | ||||
| human ABC-1 cell | Growth inhibition assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50=1.40352 μM | ||||
| human Ramos-2G6-4C10 cell | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=1.40605 μM | ||||
| human EM-2 cell | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=1.41721 μM | ||||
| human NB14 cell | Growth inhibition assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50=1.55621 μM | ||||
| human MOLT-13 cell | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=1.56706 μM | ||||
| human ECC10 cell | Growth inhibition assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50=1.63353 μM | ||||
| human LK-2 cell | Growth inhibition assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50=1.64594 μM | ||||
| human CTB-1 cell | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=1.67082 μM | ||||
| human NCI-H1581 cell | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=1.6755 μM | ||||
| human COLO-800 cell | Growth inhibition assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50=1.70382 μM | ||||
| human NB7 cell | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50=1.75297 μM | ||||
| human LAMA-84 cell | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=1.7552 μM | ||||
| human HCT-116 cells | Growth inhibition assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50=1.80908 μM | ||||
| SK-UT-1 cell | Growth inhibition assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50=1.8153 μM | ||||
| human H4 cell | Growth inhibition assay | Inhibition of human H4 cell growth in a cell viability assay, IC50=1.81578 μM | ||||
| human CAL-51 cell | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=1.83845 μM | ||||
| human LoVo cells | Proliferation assay | 72 h | Antiproliferative activity against human LoVo cells after 72 hrs by MTT-based WST8 reagent assay, IC50=1.9 μM | |||
| human HN cell | Growth inhibition assay | Inhibition of human HN cell growth in a cell viability assay, IC50=1.9251 μM | ||||
| human L-363 cell | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50=1.9512 μM | ||||
| human NCI-H747 cell | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=2.03353 μM | ||||
| human A498 cell | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50=2.3669 μM | ||||
| Klik om meer experimentele gegevens over cellijnen te bekijken | ||||||
| Molecuulgewicht | 513.59 | Formule | C29H31N5O4 |
Opslag (vanaf de datum van ontvangst) | |
|---|---|---|---|---|---|
| CAS-nr. | 331771-20-1 | SDF downloaden | Opslag van stamoplossingen |
|
|
| Synoniemen | N/A | Smiles | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5 | ||
|
In vitro |
DMSO
: 103 mg/mL
(200.54 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)
Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)
Berekeningsresultaten:
Werkconcentratie: mg/ml;
Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )
Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH2O, mengen en verhelderen.
Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.
Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.
| Kenmerken |
An Aurora selective ATP-competitive inhibitor.
|
|---|---|
| Targets/IC50/Ki |
Aurora A
(Cell-free assay) 110 nM
Aurora B
(Cell-free assay) 130 nM
LCK
(Cell-free assay) 880 nM
Src
(Cell-free assay) 1.03 μM
MEK1
(Cell-free assay) 1.79 μM
|
| In vitro |
In vitro remt ZM-447439 selectief recombinante humane Aurora A en B met IC50-waarden van respectievelijk 110 en 130 nM, terwijl andere proteïnekinasen van diverse structurele typen, inclusief de mitotische kinasen CDK1 en PLK1, worden geremd met IC50-waarden >10 μM. De Aurora kinase-remmer, ZM-447439, remt de groei van alle drie de cellijnen tijd- en dosisafhankelijk met IC50-waarden van 3 μM (BON), 0,9 μM (QGP-1) en 3 μM (MIP-101) na 72 uur continue blootstelling. Bovendien induceert ZM-447439 potentieel celapoptose door DNA-fragmentatie en caspase 3- en 7-activering te bevorderen, en arresteert GEP-NET-cellen in de G0 /G1 en G2/M-fase van de Cell Cycle. In muizenembryo's resulteert de remming van Aurora kinase-activiteit door ZM-447439 in afwijkingen tijdens de mitose door de fosforylering van histone H3 serine 10 (H3S10Ph) van G2 tot metafase te reguleren met verschillende verstoringen in elke embryonale cyclus. Een recente studie toont aan dat ZM-447439 groeiremmende en pro-apoptotische effecten vertoont op cervicale kanker SiHa-cellen, en de chemosensitiviteit verhoogt. |
| Kinase Assay |
In vitro kinase-assays
|
|
Recombinant Aurora A en B worden uitgedrukt als NH2-terminale His6-getagde fusie-eiwitten met behulp van een baculovirus-expressiesysteem. Aurora A wordt gezuiverd door affiniteitschromatografie met Ni-NTA-agarose, en Aurora B wordt gezuiverd door ionenuitwisselingschromatografie met CM Sepharose Fast Flow. 1 ng gezuiverd recombinant enzym wordt toegevoegd aan een reactiecocktail die 25 mM Tris-HCl, pH 7,5, 12,5 mM KCl, 2,5 mM NaF, 0,6 mM DTT, 6,25 mM MnCl2, 10 μM peptidesubstraat, 10 μM voor Aurora A of 5 μM ATP voor Aurora B, en 0,2 μCi γ-[33P]ATP (specifieke activiteit ≥2.500 Ci/mmol) bevat, en wordt vervolgens 60 minuten bij kamertemperatuur geïncubeerd. Reacties worden gestopt door toevoeging van 20% fosforzuur, en de producten worden opgevangen op P30-nitrocellulosefilters en getest op incorporatie van 33P met een BetaplateTM-teller. Geen enzym- en geen samengestelde controlewaarden worden gebruikt om de concentratie van ZM447439 te bepalen, die 50% remming van de enzymactiviteit gaf. Verdere details zijn op aanvraag verkrijgbaar bij Nicholas Keen.
|
Referenties |
|
| Methoden | Biomarkers | Afbeeldingen | PMID |
|---|---|---|---|
| Western blot | p53 / p21 / p-p38 / p38 pHistone H3 / CEM BubR1 / MAD2 / Cyclin B1 |
|
23759594 |
| Immunofluorescence | p21 p53 Aurora B / Survivin |
|
23759594 |
Tel: +1-832-582-8158 Ext:3
Als u nog andere vragen heeft, laat dan een bericht achter.